March 11, 2023, CD BioPharma attended the 2023 Ningbo Biopharmaceutical Industry Development Summit and China-US Global Conference on New Drug Innovation and Clinical Development. During the meeting, the second "New Drug Entrepreneurship in the Bay area" project roadshow was held concurrently. The organizer invited the judges from more than 20 institutional investors from well-known domestic venture capital firms. 29 startups entered the roadshow. CD BioPharma presented our unique tumor immunotherapy strategy and antibody-cytokine fusion protein platform. After fierce competition, CD BioPharma got praises of the judges and won the first place in the Outstanding Innovation Award.
At CD BioPharma, the antibody-fusion protein CD-001 is under IND enabling development. And on the other hand, armored PD1Ab21-CD19 CAR-T cell therapy has been conducting a IIT (investigator-initiated trial) trial in a top tie hospital in Beijing. The first three patients admitted in the trial all achieved complete remission (CR) and patient safety is also well managed.
1st from left, Zhang Feng, Director of Investment Cooperation of Qianwan New District; 3rd from left, Dr Yang Naibo, CEO of CD BioPharma
At present, CD BioPharma is conducting a new round of financing to support the project R & D and to expand of the team.
The highlights of the project are as follows:
1) Leadership team with rich experience in immunology, tumor immunotherapy and drug development
2) Novel strategy and design for tumor immunotherapy
3) New Armored CAR-T therapy show excellent results in IIT
